Sagar Lonial MD

Hematologic Oncology

Professor, Hematology and Medical Oncology, Emory University School of Medicine

1365 Clifton Rd NeAtlanta, GA 30322
Phone+1 404-778-1900

Dr. Lonial is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lonial's full profile Already have an account?

Education & Training

Emory University School of MedicineFellowship, Hematology and Medical Oncology, 1997 - 2000
Baylor College of MedicineResidency, Internal Medicine, 1993 - 1997
University of Louisville School of MedicineClass of 1993

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

GA State Medical License 1997 - 2027
TX State Medical License 1995 - 1999
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Cerner Patient Portal and Powerchart, Cerner Corporation, 2013, 2015, 2017
CMS Meaningful Use Stage 2 Certification HealtheLife and PowerChart, Cerner Corporation, 2013, 2015, 2017
CMS Meaningful Use Stage 2 Certification HealtheLife and PowerChart, Cerner Corporation, 2013, 2015, 2017

Clinical Trials

Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma Start of enrollment: 2008 Dec 01
Withdrawn
Phase 1
Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma Start of enrollment: 2008 Jun 01
Completed
Phase 1
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
ACTIVE_NOT_RECRUITING
PHASE3

Publications & Presentations

PubMed

International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.
Efstathios Kastritis, Shaji K Kumar, Vincent S Rajkumar, Wee Joo Chng, Luciano Costa
Journal of Clinical Oncology. 2026-07-22
Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.
Shaji Kumar, Susanna Jacobus, Adam Cohen, Matthias Weiss, Natalie Callander
The New England Journal of Medicine. 2026-07-16
Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myeloma.
Bruno Paiva, Irene Manrique, Ethan Thompson, Timothy B Campbell, Camila Guerrero
Hemasphere. 2026-07-01

Journal Articles

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C Munshi, Larry D Anderson, Deepu Madduri, Sagar Lonial, Noopur Raje, Fabio Petrocca, Kristen Hege, The New England Journal of Medicine
Article MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation
Guojing Zhang, Fadlo R Khuri, Taofeek K Owonikoko, Conor E Steuer, Nabil F Saba, Dong M Shin, Sagar Lonial, ScienceDirect
A Phase I/II Dose-Escalation Study Investigating All-Oral Ixazomib-Melphalan-Prednisone Induction Followed by Single-Agent Ixazomib Maintenance in Transplant-Ineligibl...
Michael D Craig, Sagar Lonial, Haematologica

Abstracts/Posters

Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Amyloidosis and Waldenstr_m Macroglobulinemia (Part 2 of a 2-Part Series)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Winship Administers First U.S. Dose of Investigational in Vivo CAR-T Therapy in Multiple Myeloma TrialMay 13th, 2026
$Relapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 Review$
Relapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 ReviewFebruary 13th, 2026
$Relapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 Review$
Relapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 ReviewFebruary 3rd, 2026